Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Xiaomei Chen, Chunyan Wang, Jin Yin, Jinhuan Xu, Jia Wei*, Yicheng Zhang*

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

* yczhang@tjh.tjmu.edu.cn (YZ); jiawei@tjh.tjmu.edu.cn (JW)

Abstract

Background

Mesenchymal stem cells (MSCs) have been broadly used experimentally in various clinical contexts. The addition of MSCs to initial steroid therapy for acute graft-versus-host disease (aGVHD) may improve patient outcomes. However, investigations regarding prognostic factors affecting the efficacy of MSC therapy for steroid-refractory aGVHD remain controversial. We thus conducted a systematic review and meta-analysis of published clinical trials to determine possible prognostic factors affecting the efficacy of MSCs in treating steroid-refractory aGVHD.

Methods and Findings

Clinical trials using MSC therapy for steroid-refractory aGVHD were identified by searching PubMed and EMBASE databases. A total of 6,963 citations were reviewed, and 13 studies met the inclusion criteria. A total of 301 patients from thirteen studies were included. Of these, 136 patients showed a complete response (CR), and 69 patients displayed a partial (PR) or mixed response (MR). In total, 205 patients exhibited overall response (ORR).

Patients with skin steroid-refractory aGVHD showed a better clinical response than gastrointestinal (CR: odds ratio [OR] = 1.93, 95% confidence interval [95%CI]: 1.05–3.57, p < 0.05) and liver (CR: OR = 2.30, 95%CI: 1.12–4.69, p < 0.05, and ORR: OR = 2.93, 95%CI: 1.06–8.08, p < 0.05) steroid-refractory aGVHD. Those with grade II steroid-refractory aGVHD exhibited a better clinical response following MSC therapy than recipients with grade III–IV (CR: OR = 3.22, 95%CI: 1.24–8.34, p < 0.05). Completion therapy may improve the CR but reduce ORR compared with induction therapy (CR: OR = 0.20, 95%CI: 0.09–0.44, p < 0.05; ORR: OR = 2.18, 95%CI: 1.17–4.05, p = 0.01). There was also a trend...
towards a better clinical response in children compared with adults (CR: OR = 2.41, 95%CI: 1.01–5.73, p = 0.05).

Conclusions
Age, skin involvement, lower aGVHD grade, and the number of infusions are the main prognostic factors affecting the efficacy of MSC therapy for steroid-refractory aGVHD.

Introduction
Allogeneic hematopoietic-stem-cell transplantation (allo-HSCT) is the treatment of choice for many malignant and non-malignant hematological diseases [1]. Following allo-HSCT, acute graft-versus-host disease (aGVHD) is a life-threatening complication associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy [2, 3]. Steroid is the initial treatment for controlling aGVHD; however, in 30–50% of patients, aGVHD is not controlled with first-line steroid therapy and requires further therapeutic intervention [4]. In a retrospective analysis of 864 patients with aGVHD [5], patients who failed to respond to therapy at day 28 after initial treatment were 2.78 times more likely to experience higher treatment-related mortality compared with those who demonstrated a response. Thus, the outcomes for non-responders are poor, and those patients who failed to respond to the initial treatment warrant a better second-line therapy.

Although prophylaxis for aGVHD and primary therapy with steroid is well established, second-line therapy is uncertain. Second-line agents include anti-thymocyte globulin [6, 7], visilizumab [8], denileukin difftox [9], daclizumab [10–12], infliximab [13, 14], etanercept [15], psoralen and ultraviolet light A therapy [16], extracorporeal photopheresis [17–19], mycophenolate mofetil [20, 21], sirolimus [22], and pentostatin [23]. Despite these second-line treatments, the prognosis for steroid-refractory aGVHD remains disappointing owing to a higher risk of infectious complications, immunosuppression-related toxicity, and incomplete GVHD remission [24, 25]. The development of a better treatment strategy for steroid-refractory aGVHD is important to improve long-term survival for allo-HSCT recipients.

Among the most recent therapeutic methods for steroid-refractory aGVHD, mesenchymal stem cells (MSCs) hold a relatively crucial position. These are multipotent progenitor cells that exhibit extensive immunomodulatory properties. They inhibit the T and B cell response by arresting them in the G0/G1 phase of the cell cycle, prevent the antigen-presenting function of monocytes, and increase regulatory T cell expansion. Additionally, MSCs are known to escape immune rejection, thus allowing their use in a human leukocyte antigen-mismatched setting [26, 27].

Based upon early results of MSCs for the treatment of steroid-refractory aGVHD and an encouraging safety profile, many studies have been conducted to determine whether the addition of MSCs to initial steroid therapy for aGVHD would improve patient outcomes. Most studies identified MSCs as a promising treatment for severe steroid-resistant aGVHD. However, investigations regarding factors affecting the efficacy of MSC therapy for steroid-refractory aGVHD remain controversial. Some data exhibited a better clinical response in skin steroid-refractory aGVHD [28–33], some hinted at a better clinical response in gastrointestinal (GI) steroid-refractory aGVHD [34], whereas others showed no difference in response [35]. In addition, it is also unclear whether children showed a better clinical response compared with adults, whether fewer organs involved indicated a better clinical response than more organs
involved—for example, some recipients only had skin steroid-refractory aGVHD while others may suffer from skin, GI, and liver steroid-refractory aGVHD, whether grade II steroid-refractory aGVHD showed a better clinical response than grade III–IV steroid-refractory aGVHD, or whether additional infusion of MSCs can improve the clinical response. Each of these factors has exhibited controversy. To help provide clarification, we conducted a systematic review and meta-analysis. We propose that through confirmation of these relationships, we will provide doctors with better guidance and support planning for treatment in steroid-refractory aGVHD.

Material and Methods
Identification and inclusion criteria of relevant studies
A bibliographic search was performed on the PubMed and Embase databases for studies investigating factors affecting the efficacy of MSCs in steroid-refractory aGVHD; studies from January 1974 to March 2015 were included in the search. The search strategies were as follows: (MSC OR mesenchymal stem cell) AND (GVHD OR graft versus host disease); results were limited to human studies and those published in English. Manual searches of reference lists from potentially relevant papers were also performed to identify any additional studies that may have been missed in the database search.

Inclusion criteria
Only data from full, published papers (no meeting or conference abstracts or letters or case reports) were used. Studies included in this meta-analysis had to (a) use MSCs for the treatment of refractory aGVHD, (b) report factors affecting the efficacy of MSCs for treating steroid-refractory aGVHD, and (c) be written in English. Review articles and duplicate publications were excluded. Each article was checked independently for inclusion and exclusion criteria by two investigators (Chen and Wang). All manuscripts were reviewed to obtain the most complete information possible.

Data extraction
Two investigators (Chen and Wang) performed double-blinded data extraction and methodological quality assessment. Data extracted from these studies included the first author, published year, nation of corresponding author, number of patients, donor type, patient age, patient sex, source of stem cells, number of children and adults, underlying diseases, conditioning regimen, GVHD prophylaxis, aGVHD grade, number of MSC infusions, and dose of MSCs. Two investigators (Chen and Wang) performed this work independently and reached a consensus on all items.

Definitions
Mixed response (MR) was defined as improvement in staging of one organ with no change in others; partial response (PR) was defined as a decrease in staging but no resolution of all signs; complete response (CR) included cases of resolution of all signs, and overall response (ORR) included CR, PR and MR [32]. The average dose administered and average frequency of administration of MSCs varied in different studies except for three included studies [29, 36, 37]. In their studies, patients received 8 biweekly intravenous infusions of $2 \times 10^6$ hMSCs/kg for 4 weeks (induction therapy), with an additional 4 weekly infusions after day 28 for patients who achieved either a partial or mixed response. Therapy was completed when all needed MSCs infusions were finished (completion therapy).
Statistical analyses
Odds ratios (ORs) and their corresponding 95% confidence intervals (95%CIs) were used to assess the strength of factors associated with the efficacy of MSC therapy for steroid-refractory aGVHD. Data were tested using the Mantel-Haenszel method with fixed or random effect models. A p-value less than 0.05 was considered statistically significant. All p values were obtained using a two-sided test. I² tests were performed to quantify the degree of heterogeneity between studies. Heterogeneity was considered present when the p value of Cochran’s Q test was <0.10 and the I² statistic was >50%. If significant heterogeneity existed, a random-effect model was used to pool the data; otherwise, a fixed-effect model was applied. Forest plots were used to summarize the results of included studies. Begg’s and Egger’s tests were used to examine publication bias. Two independent sample t-test was used to compare patients’ clinical response between studies using fetal bovine serum and studies using human platelet lysate as culture medium. We included studies regarding factors affecting patients’ clinical responses after receiving MSCs for steroid-refractory aGVHD. Several main factors were finally identified after full-text screening of all included articles. The pooled ORs with 95%CIs were performed for children compared to adults, one or two involved organs compared to three involved organs, one involved organ compared to two involved organs, skin compared to GI steroid-refractory aGVHD, skin involvement compared to liver involvement, GI involvement compared to liver involvement, grade II compared to grade III–IV, one infusion compared to more than one infusion and MSC induction therapy compared to completion therapy. We extracted both the complete response (CR) and overall response (ORR) as the endpoint of the clinical response. Analyses were performed using Review Manager software (v. 5.3, http://ims.cochrane.org/revman/download) and the SPSS software package (Version 19.0, SPSS Inc., Chicago, IL, USA).

Results
Literature search
A systematic search of PubMed and EMBASE databases yielded 441 and 6522 results, respectively. After removing duplicates, the titles and abstracts from the remaining 6809 studies were screened, and 25 potentially eligible studies for the meta-analysis were retained. After retrieving the full-text version of the aforementioned 25 studies, one study was excluded because they used MSCs to treat aGVHD as a first-line therapy rather than steroid-refractory aGVHD. Four studies did not provide sufficient data. Eight studies were excluded because they were not clinical trials. The literature search process is summarized in Fig 1.

Systematic review
Thirteen studies (eight prospective and five retrospective), including 333 patients, met all inclusion criteria and were included in the meta-analysis. Twenty-seven patients were diagnosed with chronic GVHD, and the data for five patients were unavailable, leaving a total of 301 patients that were included. Introna et al. [30] treated 15 children and 25 adults experiencing steroid-resistant grade II to IV GVHD, but only 12 children and 19 adults used MSCs for steroid-refractory aGVHD. Ringdén et al. [31] used MSCs to treat eight patients with grade III to IV steroid-refractory aGVHD and one with extensive chronic GVHD. Therefore, we only included the eight patients in this study. Herrmann et al. [33] undertook a phase I trial in 19 patients with steroid-refractory aGVHD and chronic GVHD using bone marrow-derived MSCs; only 12 patients were treated for steroid-refractory aGVHD. Bonin et al. [34] reported 13 patients with steroid-refractory aGVHD. However, four patients (31%) died within a period
of 28 days after the first MSC transfusion and were not included in this analysis. Lucchini et al. [35] described a multicenter study of 11 pediatric patients, of whom eight were treated for steroid-refractory aGVHD and available for meta-analysis. Pérez-Simon et al. [38] included 18 patients in their study, but only 10 developed steroid-refractory aGVHD. Sánchez-Guijo et al. [39] described sequential third-party MSC therapy for refractory aGVHD in 25 patients, but one patient’s response was not evaluable. Banc et al. [40] described 55 patients treated for steroid-refractory aGVHD, all of whom were available for the analysis. Of the included patients, 136 (45.2%) showed CR, and 69 (22.9%) patients showed PR or MR. Most studies examined MSC therapy for steroid-refractory aGVHD. Patients’ ages varied from 0.2 to 69 years. Sample sizes ranged from 6 to 75. The demographic information of these studies is listed in Table 1.

**MSC preparation and administration**

Six studies used unrelated MSCs [29, 30, 32, 35, 36, 39], seven used both related and unrelated MSCs [28–31, 33, 34, 37, 38, 40]. Ten used MSCs from mismatched donors [28–30, 32–37, 39], and three used both matched and mismatched cells [31, 38, 40]. Nine of the 12 studies cultured...
| Reference                  | Country                        | n  | Median age (range), years | Donor type | Source of Stem Cells (n) | Underlying Disease (n) | Conditioning Regimen (n) | Dose of MSC (cells per kg bodyweight) | No. of MSC infusions(n) |
|----------------------------|--------------------------------|-----|---------------------------|------------|--------------------------|------------------------|----------------------------|--------------------------------------|-------------------------|
| Blanc et al. (2008)        | Sweden, Netherlands, Italy and Australia | 55  | 22 (0.5–64)               | MRD 19, MUD 25, MMD 6, UCB 5 | BM 19, PBSC 30, BM + PBSC 1, CB 5 | leukemia 33, lymphoma 1, MM 2, MDS 6, others 13 | MAC 37, RIC 17 | 1.4 × 10⁶ (0.4–9) | one (27), two (22), three (4), four (1), five (1) |
| Fang et al. (2007)         | China                         | 6   | 40 (22–49)                | MRD 3, MUD 3          | BM2, PBSC 4                      | leukemia 6                | MAC 6                      | 1.0 × 10⁶                     | one (2), five (1)          |
| Lucchini et al. (2013)     | Italy                         | 11  | 10 (4–15)                 | unrelated 9, related 2 | BM 9, PBSC 1, CB 1            | leukemia 8, others 3   | MAC 9, RIC 2 | 1.2 × 10⁶(0.7–3.7) | one (4), two to five (7) |
| Prasad et al. (2011)       | USA                           | 12  | 6 (0.5–15)                | unrelated 10, related 2 | BM 2, PBSC 1, CB, BM + CB 1   | leukemia 6, others 6  | MAC 11, RIC 1 | 2 × 10⁵, 8 × 10⁵ | one to ten (7), more than ten (5) |
| Kurtzberg et al. (2014)    | USA, Canada, England, Italy, Finland, New Zealand, and Australia | 75  | 7.8 (0.2–17.5)            | unrelated 64, related 11 | BM 25, PBSC 16, CB 28  | leukemia 35, lymphoma 1, MDS 7, others 32 | NA                         | 2 × 10⁵                     | eight (35), twelve (40) |
| Introna et al. (2014)      | Italy                         | 40  | 27.8 (1–65)               | MRD 8, MUD 21, MMD 11 | BM 15, PBSC 20, CB 5         | malignant 36, nonmalignant 4 | MAC 18, RIC 17, other 5 | 1.5 × 10⁶                     | more than two (40)        |
| Ringtén et al. (2006)      | Sweden                        | 8   | 56 (8–61)                 | MRD 4, MUD 3, MMD 1 | BM 0, PBSC 1, CB 1         | leukemia 6, MM 1, others 2 | MAC 5, RIC 3 | 1.0 × 10⁶ (0.7–9) | one (6), two (3)           |
| Pérez-Simon et al. (2011) | Spain                         | 18  | 44 (21–66)                | MRD 7, MUD 4, MMD 7 | BM 5, PBSC 13              | NA                        | MAC 7, RIC 11 | 2 × 10⁶ (0.3–3.7) | one (5), two (7), three (1), four (4) |
| Bai et al. (2013)          | the Netherlands and Italy     | 37  | 7 (0.7–18)                | MRD 8, MUD 27, MMD 2 | BM 18, PBSC 7, CB 12       | leukemia 21, MDS 7, others 9 | TBI-based 9, chemotherapy-based 28 | 1–2 × 10⁶                  | one to two (22), three to five (12), more than six (6) |
| Bonin et al. (2009)        | Germany                       | 13  | 58 (21–69)                | unrelated 9, related 4 | PBSBC 13                    | leukemia 5, lymphoma 2, MM 3, MDS 1, others 2 | MAC 3, RIC 10 | 0.9 × 10⁶ (0.6–1.1) | one (1), two (8), three (2), four (1), five (1) |
| Herrmann et al. (2012)     | Australia                     | 19  | 50 (21–61)                | MRD 5, MUD 14        | PBSC 19                     | leukemia 14, lymphoma 2, MDS 2, others 1 | MAC 14, RIC 5 | 1.7–2.3 × 10⁶ | two (10), three (1), more than three (8) |
| Muroi et al. (2013)        | Japan                         | 14  | 52 (4–62)                 | related 2, related 12 | BM 9, PBSC 1, CB 4       | leukemia 6, lymphoma 1, MDS 3, MM 1 | MAC 11, RIC 3 | 2 × 10⁵                  | three (1), five (1), seven (1), eight (6), more than ten (5) |
| Sánchez-Guillo et al. (2014)| Spain                         | 25  | NA (20–65)                | NA              | NA                        | leukemia 6, MDS 7, others 12 | MAC 6, RIC 19 | 1.1 × 10⁶                  | two (4), three (3), four (18) |

**Abbreviations:** MRD = matched related donor; MUD = matched unrelated donor; MMD = mismatched donor; UCB = unrelated cord blood; BM = bone marrow; PBSC = peripheral blood stem cells; CB = cord blood; MM = multiple myeloma; MDS = myelodysplastic syndrome; NA = not available; MAC = myeloablative conditioning; RIC = reduced-intensity conditioning; TBI = total body irradiation.

doi:10.1371/journal.pone.0136991.t001

the MSCs in fetal bovine serum [28, 29, 31, 33–37, 40], one in human serum [38], and three in human platelet lysate [30, 32, 37]. Six of the 12 studies cryopreserved MSCs prior to administration [29, 30, 35–37, 39] and four used both fresh and cryopreserved MSCs [32–34, 40]. One study used only fresh MSCs [28], while the remainder of studies did not report this factor [31, 38]. Five studies reported the viability of prepared MSCs (range 70%–95%, median 80%) [29, 30, 33, 35, 40]. Twelve of the 13 studies derived MSCs from bone marrow, and one study used MSCs derived from adipose [28].
At present, no standard harvesting passages of MSCs are available. Therefore different harvesting passages were reported in the included studies. Eight studies reported the culture passage at MSCs harvest [31–37, 39, 40]. Only MSCs after first to fifth passage were used for therapy as reported by the aforementioned studies. Two studies administered MSCs in first to fourth passage [31, 40], two studies used MSCs in twice to third passage [33,34], one adopted MSCs in first to twice passage [32], one adopted MSCs in first to third passage [39], one study used MScs only in the third passage [35] and one administered MSCs only in the fifth passage [36]. Besides, data regarding the effect of harvesting passage on response were not available in most included studies. Studies have demonstrated that long-term passage affected the morphology and proliferation of hMSCs [41]. However, only first to fifth passages (referred to as early passage in some study [42]) were used for therapy, which minimized the effect of harvesting passage on response.

All the included studies described criteria for release of MSCs for clinical use. All of them stated that the cells were cultured negative for bacteria, mycoplasma and fungi before infusion. No homogeneous surface antigens of MSCs were identified by different studies. However, most studies identified MSCs as positive for surface antigens CD105 (SH-2) [28–37, 39, 40], CD 73 (SH-3, SH-4) [29–40], CD90 [29, 30, 32–40] and negative for markers of hematopoietic lineages CD14 [28–36, 39, 40], CD34 [28–40], and CD45 [36, 37, 39].

Toxicity
No infusion-related toxicity was observed during or immediately after the administration of MSC in most studies [28, 30–35, 37, 38, 40]. Only three studies reported possible toxicity related to infusion of MSCs [29, 36, 39]. Prasad et al [29] reported one patient transferred to the intensive care unit within 24 hours of the second hMSC infusion and the other patient with calcified ectopic lesions developed in the scalp and foot after hMSC therapy. Sánchez-Guijo [39] et al described one patient who developed a cardiac ischemic event 24 hours after the first infusion. However, those events were deemed not likely related to the hMSC infusion. Kurtzberg et al [36] mentioned one patient with infusion-related toxicity which resolved without sequelae and toxicity in 6 patients which were considered possibly related to MSCs infusion.

FCS versus platelet
No significant association was detected when comparing fetal bovine serum with human platelet lysate in the recipients’ clinical responses (CR: 0.58±0.21 VS 0.29±0.17, p>0.05; ORR: 0.74±0.19 VS 0.74±0.03, p>0.05) under two independent sample t-test.

Children vs. adults
There was a trend towards a better CR in children compared with adults after MSC infusion in steroid-refractory aGVHD (OR = 2.41, 95%CI: 1.01–5.73, p = 0.05, I² = 0%, Fig 2b). No significant difference was found between the two groups in ORR (OR = 1.36, 95%CI: 0.54–3.42, p = 0.51, I² = 48%, Fig 2a) after MSC infusion in steroid-refractory aGVHD under a fixed effect model.

Fewer involved organs vs. more involved organs
No significant association was detected when comparing one or two involved organs with three involved organs in the recipients’ clinical responses (ORR: OR = 1.91, 95%CI: 0.86–4.25, p = 0.11, I² = 0%, Fig 2c; CR: OR = 1.42, 95%CI: 0.60–3.35, p = 0.43, I² = 0%, Fig 2d) under a fixed effect model after MSC infusion in steroid-refractory aGVHD. No significant association
Fig 2. (a) Meta-analysis of the overall response (ORR) of children vs. adults after mesenchymal stem cell (MSC) infusion. (b) Meta-analysis of the complete response (CR) of children vs. adults after MSC infusion. (c) Meta-analysis of the ORR with one or two involved organs vs. three involved organs after MSC infusion. (d) Meta-analysis of the CR with one or two involved organs vs. three involved organs after MSC infusion.

doi:10.1371/journal.pone.0136991.g002
was detected when comparing one involved organs with two involved organs in the recipients’ clinical responses (ORR: OR = 0.57, 95%CI: 0.20–1.61, p = 0.28, I^2 = 0%, Fig 3a; CR: OR = 0.89, 95%CI: 0.39–2.08, p = 0.80, I^2 = 0%, Fig 3b) under a fixed effect model after MSC infusion in steroid-refractory aGVHD.

**Skin vs. GI vs. liver**

Recipients with skin steroid-refractory aGVHD showed a better CR compared with GI steroid-refractory aGVHD (OR = 1.93, 95%CI: 1.05–3.57, p = 0.04, I^2 = 0%, Fig 3d), but exhibited a similar ORR (OR = 1.37, 95% CI: 0.59–3.17, p = 0.46, I^2 = 0%, Fig 3c). Recipients with skin steroid-refractory aGVHD showed a better clinical response than patients with liver (ORR: OR = 2.93, 95% CI: 1.06–8.08, p = 0.04, I^2 = 0%, Fig 3a, and CR: OR = 2.30, 95%CI: 1.12–4.69, p = 0.02, I^2 = 0% Fig 3b, respectively) steroid-refractory aGVHD. Patients with GI and liver steroid-refractory aGVHD exhibited a similar clinical response after MSC therapy (ORR: OR = 1.74, 95%CI: 0.74–4.11, p = 0.21, I^2 = 27%, Fig 3c, and CR: OR = 1.26, 95%CI: 0.62–2.53, p = 0.52, I^2 = 0%, Fig 3d, respectively).

**Grade II vs. Grade III–IV**

Patients with grade II steroid-refractory aGVHD showed a better CR compared with recipients with grade III–IV steroid-refractory aGVHD (OR = 3.22, 95%CI: 1.24–8.34, p = 0.02, I^2 = 0%, Fig 5b), but exhibited a similar ORR (OR = 1.57, 95%CI: 0.62–3.98, p = 0.34, I^2 = 0%, Fig 5a).

**One infusion vs. more than one infusion**

No significant association was detected when comparing one infusion with more than one infusion in the recipients’ clinical responses (ORR: OR = 0.81, 95%CI: 0.22–2.92, p = 0.75, I2 = 0%, Fig 5c; CR: OR = 1.79, 95%CI: 0.51–6.30, p = 0.36, I2 = 0%, Fig 5d) under a fixed effect model in steroid-refractory aGVHD.

**Induction vs. completion therapy**

Initial responses after the first few cycles and after completion of MSC therapy were recorded. The CR upon completion therapy improved compared with the initial treatment (OR = 0.20, 95%CI: 0.09–0.44, p < 0.0001, I^2 = 0%, Fig 6b) though the ORR declined (OR = 2.18, 95%CI: 1.17–4.05, p = 0.01, I^2 = 0%, Fig 6a). This may indicate that increasing the time course of MSC infusions may improve CR but reduce ORR.

**Publication bias**

The results of Begg’s and Egger’s tests did not suggest any evidence of publication bias (Begg’s rank correction test and Egger’s regression test p values > 0.05).

**Discussion**

This systematic review, which compiled all trials regarding factors affecting the efficacy of MSC treatment in steroid-refractory aGVHD, yielded several clinically significant factors: skin involvement and lower aGVHD grade were associated with a better clinical response. Completion therapy can achieve better CR though the ORR declined. There was also a trend towards a better clinical response in children compared with adults. No infusion-related toxicity was observed during or immediately after the administration of MSC in most studies, indicating that MSCs were safe treatment for steroid-refractory aGVHD. These data are important for physicians considering MSCs for patients with steroid-refractory aGVHD.
### (a) Meta-analysis of the overall response (ORR) with one involved organ vs. two involved organs after MSC infusion.

| Study or Subgroup | 1 organ | 2 organs | Odds Ratio | 1 organ | 2 organs |
|-------------------|---------|----------|------------|---------|----------|
| Bonin 2009        | 0       | 1        | 7          | 7       | 24.2%    |
| Fang 2007         | 1       | 1        | 3          | 4       | 5.4%     |
| Hermann 2012      | 2       | 3        | 8          | 8       | 21.1%    |
| Lucchini 2010      | 4       | 6        | 1          | 2       | 5.4%     |
| Muroi K 2013       | 6       | 6        | 8          | 8       | Not estimable |
| Prasad 2011        | 5       | 5        | 5          | 5       | Not estimable |
| Pérez-Simon 2011   | 4       | 6        | 1          | 2       | 5.4%     |
| Ringde n 2006      | 2       | 3        | 4          | 4       | 16.1%    |
| Sánchez-Guilló 2014| 7       | 10       | 7          | 10      | 22.6%    |

Total (95% CI) 41 50 100.0% 0.57 [0.20, 1.61]

**Heterogeneity:** Chi² = 5.21, df = 6 (P = 0.52); I² = 0%

Test for overall effect: Z = 1.07 (P = 0.28)

### (b) Meta-analysis of the complete response (CR) with one organ vs. two involved organs after MSC infusion.

| Study or Subgroup | 1 organ | 2 organs | Odds Ratio | 1 organ | 2 organs |
|-------------------|---------|----------|------------|---------|----------|
| Ball 2013         | 5       | 5        | 8          | 11      | 4.1%     |
| Bonin 2009        | 0       | 1        | 1          | 7       | 3.9%     |
| Fang 2007         | 1       | 1        | 3          | 4       | 4.4%     |
| Hermann 2012      | 2       | 3        | 4          | 8       | 6.4%     |
| Lucchini 2010      | 3       | 6        | 0          | 2       | 3.1%     |
| Muroi K 2013       | 5       | 6        | 8          | 8       | 14.0%    |
| Prasad 2011        | 2       | 5        | 4          | 5       | 21.1%    |
| Pérez-Simon 2011   | 1       | 6        | 0          | 2       | 4.6%     |
| Ringde n 2006      | 2       | 3        | 3          | 4       | 7.5%     |
| Sánchez-Guilló 2014| 3       | 10       | 5          | 10      | 30.7%    |

Total (95% CI) 46 61 100.0% 0.89 [0.39, 2.08]

**Heterogeneity:** Chi² = 5.18, df = 9 (P = 0.82); I² = 0%

Test for overall effect: Z = 0.26 (P = 0.80)

### (c) Meta-analysis of the ORR of skin vs. gastrointestinal (GI) involvement after mesenchymal stem cell (MSC) infusion.

| Study or Subgroup | Skin | GI | Odds Ratio | Skin | GI |
|-------------------|------|----|------------|------|----|
| Bonin 2009        | 3    | 4  | 3           | 4    | 1.3% |
| Fang 2007         | 5    | 5  | 2           | 3    | 2.7% |
| Hermann 2012      | 10   | 11 | 7           | 7    | 12.0% |
| Introna 2014      | 18   | 27 | 16          | 23   | 61.6% |
| Lucchini 2010      | 3    | 6  | 2           | 4    | 12.8% |
| Prasad 2011        | 5    | 5  | 12          | 12   | Not estimable |
| Ringde n 2006      | 4    | 5  | 4           | 7    | 7.1% |

Total (95% CI) 62 64 100.0% 1.37 [0.59, 3.17]

**Heterogeneity:** Chi² = 3.07, df = 5 (P = 0.69); I² = 0%

Test for overall effect: Z = 0.74 (P = 0.46)

### (d) Meta-analysis of the CR of skin vs. gastrointestinal (GI) involvement after MSC infusion.

| Study or Subgroup | Skin | GI | Odds Ratio | Skin | GI |
|-------------------|------|----|------------|------|----|
| Ball 2013         | 17   | 30 | 19          | 32   | 53.5% |
| Bonin 2009        | 3    | 3  | 2           | 8    | 1.3% |
| Fang 2007         | 4    | 5  | 2           | 3    | 3.4% |
| Hermann 2012      | 9    | 11 | 3           | 7    | 4.5% |
| Introna 2014      | 11   | 27 | 5           | 23   | 21.5% |
| Lucchini 2010      | 3    | 6  | 2           | 4    | 8.1% |
| Prasad 2011        | 5    | 5  | 9           | 12   | 3.4% |
| Ringde n 2006      | 4    | 5  | 4           | 7    | 4.5% |

Total (95% CI) 92 96 100.0% 1.93 [1.05, 3.57]

**Heterogeneity:** Chi² = 5.81, df = 7 (P = 0.56); I² = 0%

Test for overall effect: Z = 2.10 (P = 0.04)

---

**Fig 3.** (a) Meta-analysis of the overall response (ORR) with one involved organ vs. two involved organs after MSC infusion. (b) Meta-analysis of the complete response (CR) with one organ vs. two involved organs after MSC infusion. (c) Meta-analysis of the ORR of skin vs. gastrointestinal (GI) involvement after mesenchymal stem cell (MSC) infusion. (d) Meta-analysis of the CR of skin vs. GI involvement after MSC infusion.

doi:10.1371/journal.pone.0136991.g003
The treatment of severe aGVHD continues to be very challenging. The current therapies do not offer significant benefits, and no therapy has been Federal Drug Administration-approved for the treatment of aGVHD. In general, approximately 50% of all patients with aGVHD initially respond to first-line steroid therapy. However, the response rates are still low and lot of people require further therapeutic intervention. Among the most recent therapeutic approaches for refractory aGVHD, MSCs hold a key position; however, studies concerning factors affecting the efficacy of MSC treatment in steroid-refractory aGVHD show controversial results.

In this meta-analysis, we found that age may play an important role in MSC therapy efficacy, as children tended to show a better clinical response than adults. This is supported by the findings of Zhuo et al. [43], who found that recipient age was an important contributor to the outcome of cell therapy. However, as the current results did not exhibit a significant difference, further studies to confirm this tendency are warranted. The current analysis also demonstrated that more patients with skin involvement responded favorably to MSC infusion, compared to patients with liver or GI involvement. The data provided by this meta-analysis also indicated that although patients’ ORRs were not different in terms of aGVHD severity, there was a higher degree of CR in lower grade aGVHD patients after MSC infusion, suggesting a better outcome for lower grade aGVHD after MSC treatment. In addition, there was a higher degree of CR in patients who completed therapy, suggesting that increasing the duration of infusions may improve patients’ CR when induction therapy is not satisfied. However, the ORR declined when MSCs were further infusions were done. Passages performed before harvesting MSC may have an impact on response. However, data regarding the effect of harvesting passage on response were not available in most included studies. No significant association was detected when comparing fetal bovine serum with human platelet lysate in the recipients’ clinical responses. Many studies [44, 45] suggested that platelet lysate was a suitable alternative to FBS for use in equine MSC expansion, which confirmed our conclusion. We found no differences in responses based on the number of organs involved. There was also no significant difference after MSC treatment when comparing GI and liver steroid-refractory aGVHD. Although our meta showed that no significant difference was found when comparing one infusion with more than one, and that complete therapy seemed to improve the CR but decrease ORR, these conclusions should be carefully made unless two aspects be considered: one, the studies included were too few; in addition, patients who received more than one infusion were likely to have more severe grade of aGVHD. For these patients equivalent outcome can be achieved if more than on infusion were given, indicating potential benefit of more than one infusion. The seeming decreased ORR may also disappear if more studies were included and patients were in the same condition before MSCs infusion. More prospective clinical trials are needed in the future.

At present, little is known about the mechanisms by which MSCs inhibit GVHD. In vitro, MSCs have varied effects on immune cells, including T cells, antigen-presenting cells, natural-killer cells, and B cells [46–48]. For inhibition of inflammation, MSCs may employ multiple mechanisms. The most studied and best understood potential mechanisms are direct cell-to-cell contact and paracrine regulation [49, 50]. As MSCs migrate to various tissues, the different number and proportion of migrated MSCs in different organs may possibly explain these phenomena. Although recent reports suggest a role for chemokines in human MSC migration [51], the signaling pathways responsible for their directed migration remain unknown.

Several limitations in our analysis merit consideration. First, the paucity of randomized controlled trials (RCTs) prompted us to incorporate non-randomized comparative trials to the meta-analysis. However, most comparisons were not statistically heterogeneous, which may support the hypothesis that non-randomized comparative studies did not introduce significant bias. Notwithstanding, considering meta-analysis of RCTs as the gold standard of evidence-
Fig 4. (a) Meta-analysis of the overall response (ORR) of skin vs. liver involvement after MSC infusion. (b) Meta-analysis of the complete response (CR) of skin vs. liver involvement after MSC infusion. (c) Meta-analysis of the ORR of gastrointestinal (GI) vs. liver involvement after mesenchymal stem cell (MSC) infusion. (d) Meta-analysis of the CR of GI vs. liver involvement after MSC infusion.

doi:10.1371/journal.pone.0136991.g004
based medicine, the robustness of our results may be hampered by the lack of RCTs. Second, the power of our analysis is limited by the small number of patients in each comparison. Third, no standard harvesting passages of MSCs were available at present, the difference of which may have an influence on patients’ response. However, only first to fifth passages were used for

Fig 5. (a) Meta-analysis of the overall response (ORR) of grade II vs. grade III–IV aGVHD after MSC infusion. (b) Meta-analysis of the complete response (CR) of grade II vs. grade III–IV aGVHD after MSC infusion. (c) Meta-analysis of the overall response after one infusion vs. more than one infusion. (d) Meta-analysis of the complete response after one infusion vs. more than one infusion.

doi:10.1371/journal.pone.0136991.g005
therapy, which minimized the effect of harvesting passage on response. Fourth, patients of steroid refractory aGVHD receive other drugs before and during MSCs infusions, which may also had an impact on patient response. The tapering or increasing of conventional immunosuppressive therapy after MSC administration was left to the clinical judgment of the treating teams in most studies, therefore conventional immunosuppressive therapy was not homogeneous and not able to be analyst. Besides, most studies did not discuss the effect of other drug on MSCs efficacy.

Our systematic review and meta-analysis shows that MSC therapy may have the best efficacy in patients with lower grade aGVHD and only skin involvement. When induction therapy does not achieve satisfactory results, continuing therapy may be helpful for some patients. Children tended to show better complete response than adults; this should be further investigated in more prospective randomized trials. Additional well-controlled randomized trials that further assess the feasibility of MSCs in different settings of hematological transplantations are needed.

Supporting Information

S1 PRISMA Checklist.

(DOC)

Acknowledgments

Financial disclosure: This research was supported by a grant from the National Science Foundation of China (grant no. 30971293).

Author Contributions

Conceived and designed the experiments: XC YZ. Performed the experiments: XC CW. Analyzed the data: XC JW. Contributed reagents/materials/analysis tools: JY JX. Wrote the paper: XC JW.

doi:10.1371/journal.pone.0136991.g006
References

1. Goldman JM, Baughan AS, McCarthy DM, Worsley AM, Hows JM, Gordon-Smith EC, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet. 1982; 2: 623–625. PMID: 6125773

2. Storb R, Thomas ED. Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev. 1985; 88: 215–238. PMID: 3910558

3. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation. 1985; 40: 39–44. PMID: 3892795

4. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007; 109: 2657–2662. PMID: 17110457

5. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010; 115: 5412–547. doi:10.1182/blood-2009-12-258442 PMID: 20388871

6. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant. 2001; 27: 1059–1064. PMID:11438821

7. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ, et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit anti-thymocyte globulin. J Hematother Stem Cell Res. 2000; 9: 367–374. PMID:10894358

8. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11: 465–471. PMID:15931635

9. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute-graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104: 1224–1226. PMID: 15113758

10. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000; 95: 83–89. PMID: 10607689

11. Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint MT, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008; 42: 609–617. doi:10.1038/bmt.2008.221 PMID: 18660840

12. Basara N, Blau WI, Kiehl MG, Römer E, Rudolphi M, Bischoff M, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc. 1998; 30: 4087–409. PMID: 9865306
21. Basara N, Kiehl MG, Blau W, Römer E, Bischoff M, Schmetzer B, et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc. 2001; 33: 2121–2123. PMID: 11377471

22. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001; 72: 1924–1929. PMID: 11773890

23. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005; 23: 2661–2668. PMID: 15837980

24. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007; 109: 4119–4126. PMID: 17234737

25. Perez L, Anasetti C, Pidala J. Have we improved in preventing and treating acute graft-versus-host disease? Curr Opin Hematol. 2011; 18: 408–413. doi: 10.1097/MOH.0b013e32834b6196 PMID: 21912253

26. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009; 87: S45–49. doi: 10.1097/TP.0b013e3181a285b0 PMID: 19424005

27. Dazzi F, Marelli-Berg FM. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur J Immunol. 2008; 38: 1479–1482. doi: 10.1002/eji.200838433 PMID: 18493977

28. Fang B, Song Y, Liao L, Zhang Y, Zhao RC. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc. 2007; 39: 3358–3362. PMID: 18089385

29. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011; 17: 534–541. doi: 10.1016/j.bbmt.2010.04.014 PMID: 20457269

30. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014; 20: 375–381. doi: 10.1016/j.bbmt.2013.11.033 PMID: 24321746

31. Ringdén O, Uznenel M, Rasmussen I, Remberger M, Sundberg B, Lönnes H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390–1397. PMID: 16732175

32. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009; 43: 245–251. doi: 10.1038/bmt.2008.316 PMID: 18820709

33. Herrmann R, Sturm M, Shaw K, Purtill D, Cooney J, Wright M, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012; 95: 182–188. doi: 10.1007/s12185-011-0989-2 PMID: 22183779

34. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013; 163: 501–509. doi: 10.1111/bjh.12545 PMID: 23992039

35. Lucchini G, Introna M, Dander E, Rovelli A, Balduzzi A, Bonanomi S, et al. Platelet-lysatexpended mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010; 16: 1293–1301. doi: 10.1016/j.bbmt.2010.03.017 PMID: 20350611

36. Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014; 20: 229–235. doi: 10.1016/j.bbmt.2013.11.001 PMID: 24216185

37. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/Ii study. Int J Hematol. 2013; 98: 206–213 doi: 10.1007/s12185-013-9399-4 PMID: 23860964

38. Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Diez Campelo M, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/I clinical trial. Haematologica. 2011; 96: 1072–1076. doi: 10.3324/haematol.2010.038356 PMID: 21393326

39. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20: 1580–1585. doi: 10.1016/j.bbmt.2014.06.015 PMID: 24952358
40. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579–1586. doi:10.1016/S0140-6736(08)60690-X PMID: 18468541

41. Zaim M, Karaman S, Cetin G, Isik S. Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells. Ann Hematol. 2012; 91:1175–1186. doi: 10.1007/s00277-012-1438-x PMID: 22395436

42. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129:163–173

43. Zhuo Y, Li SH, Chen MS, Wu J, Kinkaid HY, Fazel S, et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg. 2010; 139: 1286–1294. doi: 10.1016/j.jtcvs.2009.08.052 PMID: 19931095

44. Seo JP, Tsuzuki N, Haneda S, Yamada K, Furuoka H, Tabata Y, et al. Comparison of allogeneic platelet lysate and fetal bovine serum for in vitro expansion of equine bone marrow-derived mesenchymal stem cells. Res Vet Sci. 2013; 95:693–698. doi: 10.1016/j.rvsc.2013.04.024 PMID: 23683731

45. Ben Azouna N, Jenhani F, Regaya Z, Berraeis L, Ben Othman T, Ducrocq E, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012; 3:6. doi: 10.1186/scrt97 PMID: 22333342

46. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105: 1815–1822. PMID: 15494428

47. Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 321–334. PMID: 15846285

48. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Diloo D. Human bone marrow stromal cells inhibit alloreactive T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004; 103: 4619–4621. PMID: 15001472

49. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFN-gamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008; 18: 846–857. doi: 10.1038/cr.2008.80 PMID: 18607390

50. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012; 12: 574–591. PMID: 22515979

51. Bolno PB, Wechsler A, Kresh JY. Chemokine induced migration of human mesenchymal stem cells: A strategy for directing cardiac repair. J Am Coll Surg. 2004; 199: 33.